<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38911274</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2373-8731</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Transplantation direct</Title><ISOAbbreviation>Transplant Direct</ISOAbbreviation></Journal><ArticleTitle>Evaluating Islet Cell Isolation and Transplantation From Donors Following Medical Assistance in Dying.</ArticleTitle><Pagination><StartPage>e1667</StartPage><MedlinePgn>e1667</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1667</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/TXD.0000000000001667</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Limited information is available regarding outcomes of islet cell isolation (ICI) and transplantation (ITx) using medical assistance in dying (MAiD) donors. We aimed to assess the feasibility and outcomes of ICI and ITx in MAiD donors.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">ICI and ITx from MAiD were compared with donation after circulatory death (DCD) type III between 2016 and 2023. Differences of isolated islet equivalents (IEQs), numeric viability and other quantitative in vitro metabolic measures were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 81 ICIs were available of whom 34 (42%) and 47 (58%) from MAiD and DCD-III, respectively. There were no differences of pancreas and digested tissue weight and islets viability among the 2 groups; however, cold ischemic time was longer in MAiD (11.5 versus 9.1&#x2009;h; <i>P</i>&#x2005;=&#x2005;0.021). The IEQ (<i>P</i>&#x2005;&lt;&#x2005;0.001) and percent trapped (<i>P</i>&#x2005;&lt;&#x2005;0.001) were higher in the DCD-III; however, MAiD islets demonstrated a higher purity (<i>P</i>&#x2005;=&#x2005;0.020). Overall, 15 ITx were performed of whom 3 (8.8%) and 12 (25.5%) from MAiD and DCD-III, respectively (<i>P</i>&#x2005;=&#x2005;0.056). Patients had a median fasting C-peptide of 0.51&#x2009;ng/mL (interquartile range, 0.30-0.76 nmol/L), with no differences between groups (MAiD = 0.52 versus DCD-III = 0.51; <i>P</i>&#x2005;=&#x2005;0.718). The median HbA1c was 6.2% (interquartile range, 5.7%-7%) (MAiD = 6.3% versus DCD-III = 6.1%; <i>P</i>&#x2005;=&#x2005;0.815) and BETA2 scores (MAiD = 7.4 versus DCD-III = 12.8; <i>P</i>&#x2005;=&#x2005;0.229) did not differ.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">ICI from MAiD donor pancreas may be successfully transplanted with comparable outcomes to DCD-III and may be used for research. These results justify additional efforts to consider MAiD as another valuable source of grafts for ITx. Further multicenter studies and larger clinical experience are needed to validate our findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parente</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5506-224X</Identifier><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoeff</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kin</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hefler</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marfil-Garza</LastName><ForeName>Braulio A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tecnologico de Monterrey, The Institute for Obesity Research, Monterrey, CP, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Fernandez</LastName><ForeName>Norberto</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyon</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Gorman</LastName><ForeName>Doug</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dajani</LastName><ForeName>Khaled Z</ForeName><Initials>KZ</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blaire L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigam</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Patrick E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>A M James</ForeName><Initials>AMJ</Initials><AffiliationInfo><Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplant Direct</MedlineTA><NlmUniqueID>101651609</NlmUniqueID><ISSNLinking>2373-8731</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no funding or conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38911274</ArticleId><ArticleId IdType="pmc">PMC11191926</ArticleId><ArticleId IdType="doi">10.1097/TXD.0000000000001667</ArticleId><ArticleId IdType="pii">TXD-2024-0074</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Reeven M, Gilbo N, Monbaliu D, et al. . Evaluation of liver graft donation after euthanasia. JAMA Surg. 2020;155:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407314</ArticleId><ArticleId IdType="pubmed">32777007</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke PP, Skaro A, Sener A, et al. . Kidney transplant outcomes after medical assistance in dying. Can Urol Assoc J. 2022;16:E108&#x2013;E110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8932416</ArticleId><ArticleId IdType="pubmed">34582335</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Kawashima M, Kohno M, et al. . Outcomes of lung transplantation from organ donation after medical assistance in dying: first North American experience. Am J Transplant. 2022;22:1637&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">35108446</ArticleId></ArticleIdList></Reference><Reference><Citation>Organ Donation after MAiD in Canada [Internal Company Document]. Canadian Blood Services; 2021.</Citation></Reference><Reference><Citation>Wiebe K, Wilson LC, Lotherington K, et al. . Organ and tissue donation after medical assistance in dying&#x2014;guidance for policy forum participants. Deceased organ and tissue donation after medical assistance in dying: 2023 updated guidance for policy. CMAJ. 2023;195:E870&#x2013;E878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292956</ArticleId><ArticleId IdType="pubmed">37364914</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva E Silva V, Silva AR, Rochon A, et al. . Organ donation following medical assistance in dying, part I: a scoping review of legal and ethical aspects. JBI Evid Synth. 2024;22:157&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10871663</ArticleId><ArticleId IdType="pubmed">37477350</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva E Silva V, Silva AR, Rochon A, et al. . Organ donation following medical assistance in dying, part II: a scoping review of existing processes and procedures. JBI Evid Synth. 2024;22:195&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10871582</ArticleId><ArticleId IdType="pubmed">37489247</ArticleId></ArticleIdList></Reference><Reference><Citation>Marfil-Garza BA, Imes S, Verhoeff K, et al. . Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada. Lancet Diabetes Endocrinol. 2022;10:519&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">35588757</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paep DL, Van Hulle F, Ling Z, et al. . Utility of islet cell preparations from donor pancreases after euthanasia. Cell Transplant. 2022;31:9636897221096160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9125111</ArticleId><ArticleId IdType="pubmed">35583214</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeff K, Marfil-Garza BA, Dajani K, et al. . C-peptide targets and patient-centered outcomes of relevance to cellular transplantation for diabetes. Transplantation. 2023;107:774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">36253897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon J, Manning Fox JE, Spigelman AF, et al. . Research-focused isolation of human islets from donors with and without diabetes at the Alberta Diabetes Institute Isletcore. Endocrinology. 2016;157:560&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">26653569</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollen J, van Smaalen T, ten Hoopen R, et al. . Potential number of organ donors after euthanasia in Belgium. JAMA. 2017;317:1476&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pubmed">28399240</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras JL, Eckstein C, Smyth CA, et al. . Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes. 2003;52:2935&#x2013;2942.</Citation><ArticleIdList><ArticleId IdType="pubmed">14633854</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandhorst D, Iken M, Bretzel RG, et al. . Pancreas storage in oxygenated perfluorodecalin does not restore posttransplant function of isolated pig islets predamaged by warm ischemia. Xenotransplantation. 2006;13:465&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">16925671</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres A, Kin T, O&#x2019;Gorman D, et al. . Clinical islet isolation and transplantation outcomes with deceased cardiac death donors are similar to neurological determination of death donors. Transpl Int. 2016;29:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26264982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lablanche S, Vantyghem MC, Kessler L, et al. ; TRIMECO Trial Investigators. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:527&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">29776895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>